Search

Displaying results 6801 - 6810 of 7479 in total
  1. Drug

    VY-HTT01

    go.drugbank.com/drugs/DB16999
    Investigational

    VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses the canonical RNA interference pathway to selectively knock down levels of HTT mRNA.

  2. Drug

    RO7300490

    go.drugbank.com/drugs/DB17535
    Investigational

    RO7300490 is an investigational Fibroblast Activation Protein-α (FAP) targeted CD40 agonist.

  3. Drug

    FB-825

    go.drugbank.com/drugs/DB17598
    Investigational

    FB-825 is an investigational humanized monoclonal antibody that targets the CεmX domain of the membrane-bound IgE (mIgE), causing a depletion of mIgE positive B-cells.

  4. Drug

    Human ciliary neurotrophic factor, recombinant (E. coli)

    go.drugbank.com/drugs/DB17959
    Experimental

    The trials were NCT03071965, an extension study of the NT-501 CNTF implant for macular telangiectasia, and NCT01949324, a Phase 2 multicenter randomized clinical trial of CNTF for macular telangiectasia

  5. Drug

    Saprisartan

    go.drugbank.com/drugs/DB01347
    Experimental

    Saprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure.

  6. Drug

    Valbenazine

    go.drugbank.com/drugs/DB11915
    ApprovedInvestigational

    The reduction in chorea severity was observed as early as 2 weeks after starting treatment with an initial dose of 40 mg.[L47910]

  7. Drug

    SRP 299

    go.drugbank.com/drugs/DB05440
    Experimental

    Mycobacterium vaccae is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral immune activation through the activity of regulatory T-cells that surpress inappropriate Th2

  8. Drug

    Lonidamine

    go.drugbank.com/drugs/DB06266
    Investigational

    Lonidamine (LND) is a drug that interferes with energy metabolism of cancer cells, principally inhibiting aerobic glycolytic activity, by its effect on mitochondrially-bound hexokinase (HK). In such way LND could impair energy-requiring ...

  9. Drug

    GLB-001

    go.drugbank.com/drugs/DB32795
    Investigational

    GLB-001 is a orally bioavailable molecular glue degrader targeting casein kinase 1 alpha (CK1a).

  10. Drug

    PG-530742

    go.drugbank.com/drugs/DB05495
    Investigational

    PG-530742 selectively inhibits certain matrix metalloproteinases that have been implicated in the cartilage degradation that occurs in osteoarthritis. By inhibiting these MMPs, it potentially limits cartilage degradation and disease prog...